Surrey Heartlands

Joint Formulary & PAD

Infliximab - Psoriatic arthritis

You are here : Home > Formulary Search > Infliximab - Psoriatic arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravenous infusion
  • Subcutaneous injection (sc)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
ICB
NICE
Restrictions / Comments :

Documentation

Guidelines (Local)
Psoriatic Arthritis High cost immunomodulator drug pathway Apr-24.pdf
NICE Technology Appraisal
NICE TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Evidence Review
Biosimilar Infliximab - Evidence Review - May 2015

PAD Profile

ChemicalSubstance :
Infliximab
Indication :
Psoriatic arthritis
Group Name :
Keywords :
RA, Biologic, NICE, immunosuppressant, Cytokine modulator, TNF Alpha Inhibitor, DMARD, bDmard, Disease modulating, Rheumatology, biosimilar, subcutaneous, sc, prefilled pen, prefilled syringe
Brand Names Include :
Remicade, Inflectra, Remsima, Flixabi, Zessly
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Infliximab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Psoriatic arthritis.

Committee Recommendations (4)

03 Apr 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated  Psoriatic arthritis high cost immunomodulator treatment pathway.

06 Jan 21 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends the use of infliximab subcutaneous injection or infliximab intravenous infusion. Clinicians & patients will be able to choose the most appropriate product for them at the point of prescribing.

02 Dec 20 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriatic Arthritis High Cost immunomodulator Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. 

08 Jul 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.